

1 **Population scale whole genome sequencing provides novel insights into**
2 **cardiometabolic health**

3 Yajie Zhao*^{1,2}, Sam Lockhart*³, Jimmy Liu*⁴, Xihao Li*^{5,6}, Adrian Cortes², Xing Hua^{7,8},
4 Eugene J. Gardner¹, Katherine A. Kentistou¹, Yancy Lo⁴, Jonathan Davitte⁴, David B.
5 Savage³, Carolyn Buser-Doepner⁴, Ken K. Ong¹, Haoyu Zhang*⁷, Robert Scott*², Stephen
6 O’Rahilly*³, John R.B. Perry*^{3,1}

7 ¹MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of
8 Clinical Medicine, Cambridge CB2 0QQ, UK,

9 ²Human Genetics and Genomics, GSK, Stevenage SG1 2NFX, UK,

10 ³Metabolic Research Laboratory, Institute of Metabolic Science, University of Cambridge
11 School of Clinical Medicine, Cambridge CB2 0QQ, UK,

12 ⁴Human Genetics and Genomics, GSK, Collegeville PA, USA,

13 ⁵Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC,
14 USA,

15 ⁶Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA,

16 ⁷Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD,
17 USA,

18 ⁸Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer
19 Research, Leidos Biomedical Research Inc, Rockville, MD, USA

20 * denotes equal contribution

21 Correspondence to John R B Perry (John.Perry@mrc-epid.cam.ac.uk)
22

23 **Abstract**

24 In addition to its coverage of the non-coding genome, whole genome sequencing
25 (WGS) may better capture the coding genome than exome sequencing. We sought
26 to exploit this and identify novel rare, protein-coding variants associated with
27 metabolic health in newly released WGS data (N=708,956) from the UK Biobank and
28 All of Us studies. Identified genes highlight novel biological mechanisms, including
29 protein truncating variants (PTVs) in the DNA double-strand break repair gene *RIF1*
30 that have a substantial effect on body mass index (BMI, 2.66 kg/m², s.e. 0.43, *P* =
31 3.7×10⁻¹⁰). *UBR3* is an intriguing example where PTVs independently increase BMI
32 and type 2 diabetes (T2D) risk. Furthermore, PTVs in *IRS2* have a substantial effect
33 on T2D (OR 6.4 [3.7-11.3], *P* = 9.9×10⁻¹⁴, 34% case prevalence among carriers) and
34 were unexpectedly also associated with chronic kidney disease independent of
35 diabetes status, suggesting an important role for IRS-2 in maintaining renal health.
36 We identified genetic evidence of functional heterogeneity in *IRS1* and *IRS2*,
37 suggesting a greater role for IRS-1 in mediating the growth promoting effects of
38 insulin and IGF-I, while IRS-2 has a greater impact on glucose homeostasis likely
39 through its actions in the pancreatic islet and insulin target tissues. Our study
40 demonstrates that large-scale WGS provides novel mechanistic insights into human
41 metabolic phenotypes through improved capture of coding sequences.

42

43

44 Introduction

45 Genome-wide, hypothesis-free interrogation of the association between genomic
46 variants and human traits and diseases in large populations has resulted in many
47 key insights into the pathogenesis of common cardiometabolic disorders. The power
48 of this approach has increased with the availability of population-scale whole exome
49 sequencing (WES) data¹. In contrast to earlier common variant genome-wide
50 association studies (GWAS) where the majority of associated variants are non-
51 coding²⁻⁴, and the causal gene is often unclear, studies leveraging rare protein-
52 coding variation in gene-based collapsing tests more confidently identify causal
53 genes and directions of effect relative to gene function. This approach more readily
54 identifies novel causal pathways and mechanisms of disease for experimental
55 interrogation⁵.

56 A recent advance has come from the widespread adoption of whole genome
57 sequencing (WGS) in large population studies⁶. While the obvious advantage of
58 WGS above WES is its ability to interrogate the non-coding genome, it has also been
59 demonstrated that WGS identifies more functional coding variation than exome-
60 sequencing based technologies⁷.

61 Here, we sought to leverage the increased sample size and purported enhanced
62 capture of rare coding variation from UK Biobank WGS data⁷ to provide novel insight
63 into the genetic basis of two cardiometabolic traits of major significance to population
64 health; Type 2 Diabetes (T2D) and Body Mass Index (BMI). Previous large-scale
65 WES studies have identified several genes harbouring rare protein coding variants of
66 large effect for these traits⁸⁻¹² including examples where heterozygous loss of
67 function either increases (e.g. *GIGYF1* for T2D¹³, *BSN* for obesity^{9,14}) or decreases
68 the risk of disease (e.g. *MAP3K15* for T2D¹², *GPR75* for obesity⁸). By extending
69 these analyses to consider WGS data in more than 480K UK Biobank participants,
70 we identify five novel associations which we replicate in 219,015 individuals from the
71 All of Us study. These findings include T2D risk increasing PTVs in the gene *IRS2*,
72 encoding a key node in the insulin/IGF-1 signalling cascade, which also increased
73 risk of CKD independent of diabetes status, and PTVs in the ubiquitin-ligase *UBR3*
74 with independent effects on BMI and T2D risk. Together, these findings identify novel

- 75 genetic determinants of cardiometabolic risk and highlight impaired IRS2-mediated
76 signalling as an unexpected candidate mechanism of renal disease.

77 Results

78 To identify genes associated with either adult BMI or T2D risk, we performed
79 association testing using WGS data available in up to 489,941 UK Biobank
80 participants (see methods). This represents a sample size increase of up to 71,505
81 individuals compared to our recent WES analyses of the same cohort^{9,11}, attributable
82 to both an increase in the number of sequenced samples (N= 35,725) and the
83 inclusion of individuals of non-European ancestry (N= 64,609). Individual gene-
84 burden tests were performed by collapsing rare (MAF < 0.1%) variants across
85 19,457 protein-coding genes. We tested three categories of variants based on their
86 predicted functional impact: high-confidence protein-truncating variants (PTVs), and
87 two overlapping missense masks that used a REVEL¹⁵ score threshold of 0.5 or 0.7.
88 This yielded a total of 81,350 tests (40,750 tests for T2D and 40,600 tests for BMI)
89 for gene masks with at least 30 informative rare allele carriers, corresponding to a
90 conservative multiple-test corrected statistical significance threshold of $P < 6.15 \times$
91 10^{-7} (0.05/81,350).

92 Genetic association testing identified a total of 21 genes with at least one mask
93 associated at this threshold with adult BMI (n=10 genes) or T2D (n=12 genes).
94 (Figure 1 and Supplementary Table 1) The only overlapping association between the
95 two traits was with PTVs in *UBR3*. Our WGS analysis confirmed previously reported
96 gene associations using WES for BMI including PTVs and damaging missense
97 variants in *MC4R*, *UBR2*, *SLTM* and *PCSK1*, *BSN*, *APBA1* and *PTPRG*^{8,10,13,14}. Our
98 WGS analysis also confirmed previously reported gene associations using WES for
99 T2D including PTVs in *GCK*, *HNF1A*, *GIGYF1* and *TNRC6B*, and missense variants
100 with REVEL ≥ 0.7 in *IGF1R*^{11,13}. For most of these genes, we observed stronger
101 associations using WGS than we previously reported using WES, with an overall
102 29% increase in mean chi-square values for these associated genes using similar
103 variant masks. (Supplementary Table 2) Our WGS gene-burden test appeared
104 statistically well calibrated, as indicated by low exome-wide test statistic inflation (λ_{GC}
105 = 1.15 for BMI and 1.20 for T2D) and by the absence of significant associations with
106 any synonymous variant masks (included as a negative control). To replicate our
107 findings in UK Biobank WGS data, we implemented an identical variants annotation
108 workflow for genes identified from UK Biobank and run gene-burden testing using
109 WGS data derived from 219,015 participants in the All of Us studies.

110 At the three genes that we newly identified for BMI, PTVs conferred higher adult
111 BMI: *RIF1* (effect per allele = 2.66 kg/m², s.e. = 0.43, $P = 3.7 \times 10^{-10}$, carrier $n = 117$)
112 - encoding an effector in the non-homologous end-joining pathway activated in
113 response to double stranded DNA-breaks¹⁶, *UBR3* (2.41 kg/m², s.e. = 0.44, $P = 3.6$
114 $\times 10^{-8}$, carrier $n = 111$) - an E3-ubiquitin ligase that is highly expressed in sensory
115 tissues¹⁷, and the non-receptor tyrosine kinase *TNK2* (0.88 kg/m², s.e. = 0.17, $P =$
116 4.2×10^{-7} , carrier $n = 702$). Two of these three novel gene associations with BMI
117 were replicated in All of Us (at $P < 0.05$, Figure 2 and Supplementary Table 3): *RIF1*
118 (2.58 kg/m², s.e. = 1.17, $P = 2.8 \times 10^{-2}$, carrier $n = 39$) and *UBR3* (3.21 kg/m², s.e. =
119 0.84, $P = 1.3 \times 10^{-4}$, carrier $n = 67$). (Supplementary Table 4) Previous GWAS
120 studies also identified loci associated with BMI and T2D within 500kb of *RIF1* (T2D:
121 rs6567160:T, beta=0.018, s.e. = 0.003, $P = 4.1 \times 10^{-10}$) and *TNK2* (BMI:
122 rs34801745:C, beta=0.013, s.e. = 0.002, $P = 7 \times 10^{-11}$; T2D: rs6800500:C,
123 beta=0.03, s.e. = 0.003, $P = 2.4 \times 10^{-21}$). (Supplementary Table 5). Using a variant to
124 gene mapping method¹⁸(see Methods), GWAS signals at both the *RIF1* and *TNK2*
125 loci could be confidently linked to the function of these genes, e.g. we observed
126 colocalisation between eQTLs for both *RIF1* and *TNK2*, with decreased expression
127 corresponding to increased BMI, directionally concordant with their rare PTV effects
128 (Supplementary Table 5).

129 At the seven genes that have not been previously implicated via population-scale
130 studies for T2D, PTVs conferred higher risk for T2D: *IRS2* (OR per allele =6.4, 95%
131 CI [3.7-11.3], $P = 9.9 \times 10^{-14}$, carrier $n = 58$, 34% case prevalence among carriers) -
132 encoding a key adaptor molecule in the insulin-signaling cascade, *UBR3* (OR =3.4,
133 95% CI [2.1-5.2], $P = 6.1 \times 10^{-9}$, carrier $n = 115$, 23% case prevalence) - encoding a
134 component of N-terminal acetyltransferase complexes¹⁹, *NAA15* (OR =5.3, 95% CI
135 [2.6-10.6], $P = 1.2 \times 10^{-7}$, carrier $n = 39$, 31% case prevalence) and *RMC1* (OR =2.7,
136 95% CI [1.8-4.2], $P = 3.4 \times 10^{-7}$, carrier $n = 138$, 20% case prevalence) - encoding
137 part of a protein complex critical for lysosomal trafficking and autophagy^{20,21}.
138 (Supplementary Table 4) Our missense mask also identified associations with *IP6K1*
139 (OR =3.6, 95% CI [2.2-6.0], $P = 8.5 \times 10^{-9}$, carrier $n = 84$, 26% case prevalence) -
140 encoding inositol phosphokinase, the known MODY gene *HNF4A* (OR =1.5, 95% CI
141 [1.3-1.8], $P = 3.1 \times 10^{-9}$, carrier $n = 1,386$, 13% case prevalence), and *UBB* (OR

142 =3.7, 95% CI [2.1-6.4], $P = 5.8 \times 10^{-7}$, carrier $n = 66$, 26% case prevalence) -
143 encoding ubiquitin. (Supplementary Table 4)

144 Three of these seven gene associations with T2D were replicated in All of Us: *IRS2*
145 (OR =3.7, 95% CI [1.5-8.9], $P = 3.9 \times 10^{-3}$, carrier $n = 40$, 30% case prevalence),
146 *UBR3* (OR =2.7, 95% CI [1.3-5.3], $P = 5 \times 10^{-3}$, carrier $n = 67$, 25% case prevalence)
147 and *HNF4A* (missense variants with REVEL ≥ 0.7 : OR =1.6, 95% CI [1.2-2.2], $P =$
148 4.7×10^{-3} , carrier $n = 293$, 20% case prevalence; missense variants with REVEL \geq
149 0.5: OR =1.3, 95% CI [1.1-1.7], $P = 1.5 \times 10^{-2}$, carrier $n = 634$, 17% case
150 prevalence). (Supplementary Table 4)

151 There were also common GWAS loci associated with BMI and T2D within 500kb
152 from *IRS2* (T2D: rs9301365:T, beta=0.024, s.e. = 0.003, $P = 2.1 \times 10^{-16}$), *RMC1*
153 (BMI: rs891387:T, beta=0.021, s.e. = 0.002, $P = 9.3 \times 10^{-35}$; T2D: rs1788819:G,
154 beta= 0.032, s.e. = 0.003, $P = 4 \times 10^{-21}$), *IP6K1* (BMI: rs11713193:A, beta=0.025,
155 s.e. = 0.002, $P = 3 \times 10^{-48}$; T2D: rs7613875:A, beta= 0.025, s.e. = 0.003, $P = 4.8 \times$
156 10^{-16}), *HNF4A* (BMI: rs2284265:T, beta=0.012, s.e. = 0.002, $P = 4.8 \times 10^{-8}$; T2D:
157 rs12625671:C, beta= 0.067, s.e. = 0.004, $P = 1.7 \times 10^{-68}$) and *UBB* (BMI:
158 rs1075901:C, beta=0.012, s.e. = 0.002, $P = 4.4 \times 10^{-13}$)(Supplementary Table 5). Of
159 these, we could confidently link variants at the *IRS2* and *HNF4A* T2D loci with the
160 corresponding gene's function (Supplementary Table 5).

161 As a further sensitivity analyses, we performed 'leave-one-out analyses' which
162 confirmed that none of the above gene-level associations was driven by a single rare
163 variant. (Supplementary Table 6) Furthermore, all novel associations exhibited
164 similar effects in published results using WES data from UK Biobank but at sub-
165 threshold significance ($P \leq 8.3 \times 10^{-5}$).

166 To assess its added value, we compared our all-ancestries based approach to an
167 European-only analysis using otherwise identical analytical parameters. Among the
168 27 significant associations we identified, 21 had a stronger P -value in the all-
169 ancestries analysis with an overall 4.6% increase in mean chi-square values. To
170 similarly quantify the gain in statistical power using WGS, in the UK Biobank sample
171 with both WGS and WES data available we compared the gene-burden test statistics
172 from WGS and WES for the genes identified in our discovery analysis. On average,
173 we observed a 21% increase in chi-square in the WGS analysis (Supplementary

174 Table 2). Among the 26 gene-masks we compared, WGS data included (median,
175 IQR: 12, 4-16) more variants compared to WES. Moreover, sensitivity gene-burden
176 tests considering only those additional carriers identified by WGS (i.e. not identified
177 by WES data), 16 of the 23 gene-mask combinations with at least 5 carriers showed
178 a nominally significant association ($P < 0.05$) with the target phenotype, indicating
179 that additional coding variants identified by WGS are likely to be functionally
180 relevant. In contrast, some variants were identified by WES-only. Gene masks of
181 these variants (with at least 5 carriers) showed not even nominal significant
182 association with the target phenotype. Our findings confirm and quantify the
183 enhanced coverage of coding variants provided by WGS above WES in UK Biobank.

184

185 **A phenotypic association scan of identified genes reveals a novel role for *IRS2*** 186 **in human kidney health**

187 To explore the broader phenotypic effects of our identified BMI-raising and T2D risk
188 genes we conducted a phenotypic association scan for each gene variant mask
189 significantly associated with T2D and BMI in our discovery analysis. (Supplementary
190 Table 7 and 8). We observed several expected associations, for example between
191 T2D risk genes with HbA1c and glucose and between BMI genes with whole body fat
192 mass (Supplementary Figure 3). However, we were intrigued to observe a novel,
193 highly statistically significant association of *IRS2* PTVs with lower Cystatin-C-derived
194 estimated glomerular filtration rate (eGFR, effect = $-12.92 \text{ mL/min/1.73m}^2$, s.e. =
195 1.87 , $P = 4.9 \times 10^{-12}$, carrier $n = 55$). This effect of *IRS2* PTVs on renal function was
196 consistently observed across three different methods of GFR estimation (Figure 4).
197 This association does not simply reflect the consequences of T2D-mediated chronic
198 hyperglycaemia on renal function as it was also observed in carriers of PTVs in *IRS2*
199 without a diagnosis of T2D (Cystatin-C-derived eGFR: effect = -10.42
200 mL/min/1.73m^2 , s.e. = 2.24 , $P = 3.3 \times 10^{-6}$, carrier $n = 36$). Consistent with a
201 renoprotective role for IRS-2 in humans, PTVs in *IRS2* were associated with a ~4-
202 fold increase in odds of chronic kidney disease (CKD) (OR = 4.0 , 95% CI [1.9 - 8.6] P
203 = 3.1×10^{-4} , carrier $n = 58$, 14% case prevalence, Figure 4). These results identify
204 *IRS2* as a T2D risk gene with an independent effect on CKD risk.

205 We also observed that PTVs in the adaptor protein *GIGYF1* conferred beneficial
206 effects on serum lipids, consistent with previous findings²², but deleterious effects on
207 renal function including a ~2-fold increase in odds of CKD (Supplementary Table 7
208 and Figure 3). We also note a striking reduction in circulating SHBG (sex hormone
209 binding globulin) levels in carriers of predicted damaging missense mutations in
210 *HNF4A* (effect = -6.4 nmol/L, s.e. = 0.73, $P = 7.5 \times 10^{-19}$, carrier $n = 1200$), which
211 has been reported to regulate *SHBG* transcription *in vitro*²³. PTVs in *RMC1* conferred
212 higher triglycerides, lower HDL (and therefore higher TG:HDL ratio) and increased
213 risk of algorithmically defined MAFLD, a pattern of association suggestive of lipotoxic
214 insulin resistance.

215

216 **Evidence of functional diversity in IRS1/IRS2 mediated signalling**

217 IRS-1 and IRS-2 are critical nodes in the insulin/IGF-1 signalling cascade. They are
218 recruited to and phosphorylated by the activated insulin receptor, serving as
219 essential adaptor molecules to mediate downstream signalling. An interesting finding
220 from mouse genetic studies is that *IRS1*-knockout mice do not show fasting
221 hyperglycaemia, despite evidence of insulin resistance and reduced body size,
222 consistent with impaired growth due to IGF-1-resistance^{24,25}. In contrast, *IRS2*-
223 knockout mice are comparable in size to their littermate controls but exhibit fasting
224 hyperglycaemia and glucose intolerance due to failed beta-cell compensation²⁶. To
225 determine if similar phenotypic heterogeneity is present in humans, we compared the
226 effects of *IRS1* and *IRS2* loss of function. (Supplementary Table 7 and 8) Consistent
227 with the described mouse biology, human carriers of PTVs in *IRS1* had reduced fat-
228 free mass and reduced height – suggestive of impairment in the anabolic effects of
229 IGF-1 signalling. In contrast, carriers of PTVs in *IRS2* had no changes in lean mass
230 or height, but a substantially increased risk of T2D (Figure 5). These findings
231 suggest that the functional specificity of IRS-1/IRS-2 previously described in mice is
232 conserved in humans; IRS-1 likely mediates the effects of IGF-1 signalling on linear
233 growth and lean mass, whereas IRS-2 is relatively more important for glucose
234 tolerance, likely due to its key regulatory actions in the pancreatic beta cell.

235

236 **E3-ubiquitin ligases UBR2 and UBR3, body composition and type 2 diabetes**
237 **risk**

238 *UBR2* and *UBR3* are related E3-ubiquitin ligases. *UBR2* is a canonical N-recogin
239 which recognises modified N-terminal amino acid residues (so-called N-degrons)
240 and ubiquitinates these proteins to target them for degradation^{27,28}. *UBR3* shares
241 weak homology to *UBR2* and while it contains a UBR-domain which mediates
242 recognition of modified amino acids by *UBR2*, it does not possess N-recogin activity
243 but does mediate N-terminal ubiquitination via an as of yet unknown degradation
244 signal^{27,29}. In our discovery analyses, *UBR2* and *UBR3* PTVs were both associated
245 with increased BMI, but only *UBR3* conferred a significant increase in T2D risk
246 (Figure 1 and 3), consistent with distinct molecular actions of these proteins.
247 Importantly, the association of PTV in *UBR3* and T2D was not solely due to
248 increased BMI as the effect on T2D was only partially attenuated after adjustment for
249 BMI (OR =2.5, 95% CI [1.5-4.1], $P = 2.7 \times 10^{-4}$). To gain further insight into the
250 mechanism through which *UBR3* disruption increases T2D risk, we examined
251 associations with body fat distribution and surrogate markers of insulin resistance
252 measured in UKBB, SHBG and TG:HDL (Supplementary Table 8). We found no
253 evidence for an effect of PTVs in *UBR3* on body fat distribution as assessed by
254 WHRadjBMI and inconsistent effects on the surrogate markers of insulin resistance
255 TG:HDL, which was not regulated, and SHBG which was nominally decreased.
256 Interestingly, *UBR2* has been implicated in regulation of muscle mass in several
257 mouse studies^{30–32}. Therefore, we assessed the effect of *UBR2* and *UBR3* PTVs on
258 lean and fat mass measured by bioimpedance in UK Biobank. Carriage of a PTV in
259 *UBR2* or *UBR3* conferred higher whole body fat mass and, while *UBR2* PTV carriers
260 showed a nominal increase in whole body fat free mass, this association was modest
261 and likely to be a secondary effect of increased adiposity (Supplementary Table 8).
262 While we did not observe any notable effects of *UBR3* PTVs on fat-free mass
263 measurements, maximum hand-grip strength was nominally increased
264 (Supplementary Table 8).

265

266 Discussion

267 By conducting the first genome-wide multi-ancestry gene burden test using WGS
268 data from a cumulative total of >700,000 individuals, we identified several novel BMI
269 and T2D-associated genes. Compared with previous European-only analysis based
270 on WES data, we increased carrier number and statistical power by incorporating all
271 individuals with available WGS data. Importantly, we demonstrate that our findings
272 from UK Biobank are robust and reproducible, as several were replicated in an
273 independent US population-based study (All of Us) which has considerably different
274 demographics, notably its younger age, higher baseline prevalence of T2D and
275 enhanced ethnic diversity³³.

276 Our study also highlights some emerging challenges in conducting rare-variant
277 association studies across diverse populations. For example, we failed to replicate
278 two gene masks using All of Us data – *GCK* (Missense variants, REVEL \geq 0.5) and
279 *IGF1R* (REVEL \geq 0.7). Both genes are robustly associated with T2D in UK Biobank,
280 have >100 informative carriers in the All of Us cohort and have a high probability of
281 being true based on either known clinical associations with T2D (*GCK*) or orthogonal
282 support from common variant association studies (*IGF1R*)¹¹. This may reflect specific
283 challenges in the fidelity of missense classification tools across different pools of rare
284 missense variants present in different cohorts with varying ethnic composition.

285 Our results provide several novel biological insights into the determinants of human
286 cardiometabolic health. The association with *RIF1*, a gene implicated in telomere
287 regulation, DNA repair and replication timing, expands the list of DNA damage
288 response genes involved in metabolic health¹⁰. The biological mechanisms behind
289 these associations remain unclear. However, as the same variants in *RIF1* showed
290 not even nominal association with recalled childhood adiposity in UK Biobank
291 ($P>0.05$), contrasting with their robust association with adult BMI ($P = 3.7 \times 10^{-10}$),
292 we speculate that mechanisms that regulate neuronal degeneration might influence
293 risk of adult-onset obesity⁹.

294 We identified a robust, replicable association of PTVs in the critical signalling node in
295 the insulin/IGF1-pathway, IRS-2, and T2D with carriers exhibiting >3.6-fold increase
296 in odds of diagnosis with T2D (OR 3.68 in All of US and 6.45 in UK Biobank). While
297 insulin resistance is well known as a necessary antecedent to the development of

298 T2D, there is a longstanding interest in discerning the role of specific nodes in the
299 insulin signalling cascade in the development of insulin resistance and its related
300 complications. By necessity, this work has largely been done in animal models and
301 the translational relevance of these findings to human health is uncertain. Candidate-
302 gene testing and exome-sequencing studies of probands with extreme phenotypes
303 identified in the clinical setting have been leveraged to provide insight into the
304 function of several nodes of the insulin-signalling cascade in humans (*INSR*, *PIK3R1*
305 and *AKT2*)^{34–39}, but our findings place *IRS2* as the first component of the insulin
306 signalling cascade to be definitively linked to T2D via study of rare LOF variants
307 using an unbiased population-based sequencing approach.

308 To gain further insight into the specific phenotypic consequences of insulin/IGF1
309 resistance mediated by *IRS2* PTVs, we compared carriers of these variants with
310 carriers of the other broadly expressed IRS protein, IRS-1. We found that PTVs in
311 *IRS1* conferred a much more modest effect on T2D risk compared to *IRS2*, but
312 significantly reduced height and lean mass, phenotypes which were not associated
313 with *IRS2* PTVs. These findings recapitulate observations first made in lower
314 organisms – *IRS1* knockout mice are insulin resistant and small but develop only
315 modest dysglycaemia due to compensatory changes in the beta-cell^{24,25}. In contrast,
316 *IRS2* knockout mice grow normally, and exhibit significant hepatic and skeletal
317 muscle insulin resistance, but in contrast to their *IRS1* counterparts develop severe
318 dysglycaemia due to beta-cell failure²⁶. Our results suggest that functional
319 heterogeneity in IRS-1/IRS-2-mediated insulin/IGF1-signaling is conserved across
320 species and is consistent with an important function of IRS-2 in human beta-cell
321 health, as has been demonstrated in mice⁴⁰. Future recall by genotype studies of
322 *IRS2* PTV carriers with detailed assessment of glucose homeostasis and insulin
323 sensitivity will be key in determining the relative contribution of insulin resistance and
324 beta-cell failure to the development of T2D in *IRS2*-haploinsufficiency.

325 To gain a broader perspective of the effects of T2D risk and BMI-raising genes we
326 conducted a phenotypic association scan for these genes. Remarkably, we observed
327 that PTVs in *IRS2* significantly reduce eGFR independent of T2D status and cause a
328 4-fold increase in the odds of algorithmically defined CKD in UK Biobank.
329 Furthermore, T2D risk genes did not generally increase CKD risk in UK Biobank
330 indicating this is a specific effect of IRS-2 disruption. While the mechanistic basis of

331 this association requires elucidation, insulin signalling exerts salutatory effects on
332 podocyte health and function in mice^{41–43} and germline loss of *IRS2* in mice results in
333 smaller kidneys⁴⁴. Both mechanisms could contribute to the adverse effects of PTVs
334 in *IRS2*; podocyte dysfunction and loss is a key early step in many forms of kidney
335 disease including diabetic nephropathy and there is an increasing appreciation that
336 the nephron number at birth - nephron endowment - is an important determinant of
337 kidney health in later life^{45,46}, so both of these potential pathogenic mechanisms
338 could be involved. Our demonstration of a causal role for *IRS2* in kidney health
339 provides an important impetus to determine if effects on renal health are mediated by
340 a role of IRS-2 in kidney development and nephrogenesis or by a regulatory role in
341 post-natal renal physiology. If a renoprotective function of IRS-2 in post-natal life
342 exists, then examining the effects of risk factors for renal disease such as diabetes
343 and obesity on IRS-2-mediated signalling could highlight a novel and potentially
344 modifiable mechanism of kidney disease.

345 Our findings regarding IRS-2 and T2D may be of broad relevance to patients with
346 T2D; it has long been postulated that acquired IRS-2 dysfunction could play a key
347 role in the aetiology of polygenic T2D given its role in two key pathophysiological
348 processes – insulin resistance and pancreatic beta-cell failure^{47,48}. Interestingly, a
349 recently described subtype of T2D, severe insulin resistant diabetes (SIRD),
350 presents with reduced eGFR at T2D diagnosis and increased CKD risk that does not
351 seem to be solely related to glycaemic control⁴⁹. Our results highlight impaired IRS-
352 2-signalling as a candidate mechanism in the pathogenesis of this diabetes subtype.

353 An intriguing finding was the association of the related *UBR2* and *UBR3* with BMI,
354 with the latter also elevating T2D risk in a manner only partially dependent on its
355 effect on BMI. *UBR2* has previously been associated with increased BMI in WES
356 analysis⁸, but this is the first report of damaging mutations in *UBR3* with any
357 cardiometabolic phenotype, to our knowledge. These proteins are both E3-ubiquitin
358 ligases; *UBR2* functions as an effector of the N-degron pathway recognising
359 modified N-Terminal amino acids and targeting their host protein for degradation,
360 while *UBR3*, despite structural homology to *UBR2*, lacks canonical N-recognin
361 activity^{27,28}. Interestingly, while both *UBR2* and *UBR3* are relatively broadly
362 expressed, *UBR3* is enriched in a number of sensory tissues including tongue, ear
363 and olfactory epithelia – which may have relevance to its effects on BMI¹⁷. Both


364 UBR2 and UBR3 are relatively enriched in expression in skeletal muscle. While the
365 specific effects of these proteins in muscle is unclear, UBR3 may play a non-
366 redundant role in skeletal muscle function as carriers of PTVs in *UBR3* had
367 reductions in grip strength. While our work clearly highlights UBR2 and UBR3 as
368 important regulators of cardiometabolic health, further study exploring their
369 substrates and function are necessary to gain a mechanistic understanding of their
370 effects on BMI and T2D.

371 There are some potential clinical implications of our findings. Notably, in a
372 phenotypic association scan of potentially relevant traits we observed a strong
373 association between predicted damaging missense mutations in *HNF4A* and
374 reduced circulating SHBG. While it has been noted that *HNF4A* can activate the
375 SHBG promoter²³ and a causal relationship between *HNF4A* and circulating SHBG
376 has been suggested⁵⁰, this is the first such genetic evidence in humans. Pathogenic
377 mutations in *HNF4A* cause a type of monogenic diabetes onset of the young
378 (MODY) - we speculate that individuals with apparent T2D and low SHBG without
379 significant insulin resistance may be enriched for *HNF4A* mutations. We have also
380 identified the first phenotypic consequences of loss of *IRS2* in humans; while
381 damaging mutations in other components of the insulin signalling cascade are
382 reported to cause severe monogenic insulin resistance, the impact of *IRS-2*
383 disruption in humans was undocumented. Our work provides an impetus for
384 research-based genetic testing of individuals with T2D and features of severe insulin
385 resistance and in other cases of atypical diabetes⁵¹, particularly if they also have
386 CKD and/or a monogenic cause is suspected. More generally, it is interesting to
387 speculate that as sample sizes grow, insights from population genetic association
388 studies could increasingly inform clinical intuition regarding the aetiology of diabetes
389 by identification of robustly associated biomarkers in an unbiased manner.

390 In summary, our study expands the number of genes directly implicated in metabolic
391 health by human gene knockouts, and further illustrates the benefit of genome over
392 exome sequencing for the discovery of rare variants associated with disease.

393

394 **Figures**




395

396 **Figure 1 | Genome-wide multi-ancestry gene burden test for BMI (top panel) and T2D**
397 **(bottom panel) in UK Biobank.** Manhattan plots showing gene burden test results for BMI
398 and T2D. Genes passing exome-wide significance ($P < 6.15 \times 10^{-7}$ (0.05/81,350)) are
399 labelled. Points are annotated with variant predicted functional mask (MISS REVEL;
400 missense variants with REVEL scores (above 0.5 or 0.7), HC PTV; high confidence protein
401 truncating variants).

402

403

404



405

406

407

408

409

410

411

412

413

414

415

416


417

418

419

420


Figure 2 | Discovery and replication of significant associations with BMI (left) and T2D (right) in UK Biobank and All of Us study. For single genes with multiple significant associations, only the most significant association is displayed. Odds of T2D are plotted on a Log₁₀-scale.




421

422 **Figure 3 | Phenotypic association scans of BMI (top) and T2D (bottom)**
 423 **associated genes in UK Biobank. The most significant Gene x Mask association**
 424 **with BMI or T2D was assessed on a panel of 79 traits (see methods). Dots are**
 425 **coloured according to classification of phenotype; the orientation of triangles indicate**
 426 **the direction of effect for significant traits. For clarity, only a subset of traits and the**
 427 **most significant Gene x Mask association (for genes with >1 mask significantly**
 428 **associated with T2D or BMI) are displayed. *UBR3*, which was associated with both**
 429 **T2D and BMI in our discovery analysis is presented alongside BMI risk genes only to**
 430 **avoid duplication. The solid horizontal lines represent a Bonferroni-corrected**
 431 **threshold for statistical significance of 2.35×10^{-5} ($0.05/2132$ Phenotype x Mask**
 432 **associations).**

A



B




433

434 **Figure 4 | Loss of function mutations in *IRS2* increase CKD risk.** **A:** The effect of
 435 protein truncating variants in *IRS2* on various measures of eGFR (ml/min/1.73m²)
 436 and algorithmically defined CKD (OR) and P-values from linear and logistic
 437 regression, respectively are illustrated. Odds of CKD are plotted on log-scale. **B:** The
 438 effect of rare predicted damaging mutations in the labelled genes on T2D risk are
 439 plotted against the effect on eGFR (across three different methods of estimation) to
 440 illustrate that the effect of PTVs in *IRS2* on renal function appear independent of its
 441 effect on T2D. For clarity, only the gene x mask combination most significantly
 442 associated with T2D is plotted.

443

444



445

446 **Figure 5 | Genetic evidence for functional heterogeneity of insulin receptor**
447 **substrates in humans.** Studies in mice have demonstrated that loss of IRS-1
448 markedly reduces body size with a modest effect on blood glucose, whereas loss of
449 IRS-2 causes severe hyperglycaemia without affecting body size. We identify
450 consistently divergent effects of PTVs in *IRS1* and *IRS2* in humans. Effect of PTVs in
451 *IRS1* and *IRS2* on continuous traits are plotted as standardised betas and as odds
452 ratio for T2D. Odds of T2D are plotted on a Log-scale.

453

454

455

456

457 **Methods**

458 **UK Biobank whole genome sequencing data processing**

459 The whole genome sequencing (WGS) of UK Biobank participants is described in
460 detail in Li et al.⁷ In brief, 490,640 UK Biobank participants were sequenced to an
461 average depth of 32.5X using Illumina NovaSeq 6000 platform. Variants were jointly
462 called using GraphTyper⁵², which resulted in 1,037,556,156 and 101,188,713 high
463 quality (AAScore < 0.5 and <5 duplicate inconsistencies) SNPs and indels
464 respectively.

465 We further processed the jointly called genotype data in Hail v0.2⁵³, where multi-
466 allelic sites were first split and normalized. Variants were then filtered based on low
467 allelic balance (ABHet < 0.175, ABHom < 0.9), low quality-by-depth normalized
468 score (QD < 6), low phred-scaled quality score (QUAL < 10) and high missingness
469 (call rate < 90%). For the analysis in the European ancestry cohort (see below), we
470 further removed variants that failed test for Hardy-Weinberg equilibrium ($P < 1e-100$)
471 within this cohort.

472 Variants were annotated using Ensembl Variant Effect Predictor (VEP)⁵⁴ v108.2 with
473 the LOFTEE plugin⁵⁵. Combined Annotation-Dependent Depletion (CADD)
474 annotations were based on precomputed CADD⁵⁶ v1.7 annotations for all SNPs and
475 gnomAD v4 indels. REVEL (rare exome variant ensemble learner)¹⁵ annotations
476 were obtained from the May 3, 2021 release of precomputed REVEL scores for all
477 SNPs. We prioritized the individual consequence for each variant based on severity
478 which was defined by VEP. The protein-truncating variant (PTV) category is the
479 combination of stop-gained, splice acceptor, and splice donor variants. The
480 missense and synonymous variants were adopted directly from VEP. Only the
481 variants on autosomes and the chromosome X, which were within ENSEMBL
482 protein-coding transcripts, were included in our downstream analysis.

483

484

485

486

487 **European ancestry definition in UK Biobank WGS**

488 We defined a European-ancestry cohort to be that which most resembled the NFE
489 (non-Finnish European) population as labelled in the gnomAD v3.1 dataset⁵⁵. This
490 NFE group was one of nine ancestry groups labelled in gnomAD, which was based
491 on HGDP and 1000 Genome samples. Variant loadings for 76,399 high-quality
492 informative variants from gnomAD were used to project the first 16 principal
493 components onto all UK Biobank WGS samples. A random forest classifier trained
494 on the nine ancestry labels in gnomAD was then used to calculate probabilities that
495 reflect the similarity between the UK Biobank participant and each of the gnomAD
496 ancestry labels.

497

498 **Genome-wide gene burden testing in the UK Biobank**

499 BOLT-LMM⁵⁷ v2.4.1 was used as our primary analytical software to conduct gene
500 burden tests.

501 To run BOLT-LMM, we first derived a set of genotypes consisting of common (MAF >
502 0.01) LD-pruned ($LD\ r^2 < 0.1$) variants in individuals with WGS data to build the null
503 model. Pruning was conducted using PLINK2⁵⁸ on a random subset of 50,000
504 individuals (options in effect: --maf 0.01 --thin-indiv-count 50000 --indep-pairwise
505 1000kb 0.1).

506 We adopted the same strategies used in our previous analyses using WES data^{9,11}.
507 We generate the dummy genotype files in which each gene-mask combination was
508 represented by a single variant, which were required as the genotype input for
509 BOLT-LMM. We then coded individuals with a qualifying variant within a gene as
510 heterozygous, regardless of the total number of variants they carried in that gene.
511 We then created the dummy genotypes for the MAF < 0.1% high confidence PTVs
512 as defined by LOFTEE, missense variants with REVEL > 0.5 and missense variants
513 with REVEL > 0.7. After getting all required inputs, BOLT-LMM was used to analyse
514 BMI and T2D using default parameters except for the inclusion of the 'ImmInfOnly'
515 flag. The covariates included in our analysis are age, age2, sex, age*sex, the first 20
516 principal components as calculated from all WGS samples, and the WGS-released
517 batch. Different from our previous studies, we included all samples without restricting

518 their ancestries to maximise the sample size. Only samples who withdrew consent or
519 had missing phenotypes and covariates were excluded; filtering resulted in 481,137
520 and 489,941 samples remaining for BMI and T2D, respectively.

521 To identify single variants driving a given association within a single gene, we
522 performed a leave-one-out analysis for all identified genes using a generalized linear
523 model in R v4.0.2 by dropping the variants contained in the gene-mask combination
524 one at a time.

525 As BOLT-LMM use a linear mixed model, we estimated and reported the OR using
526 the generalized linear model in R v4.0.2 for all T2D associated genes.

527

528 **Replication in All of Us study**

529 Participants analyzed in this study were selected from the All of Us (AoU) Research
530 Program cohort³³. The collection of participant information adhered to the AoU
531 Research Program Operational Protocol ([https://allofus.nih.gov/sites/default/files/All
532 of_Us_Research_Program_Operational_Protocol_2022.pdf](https://allofus.nih.gov/sites/default/files/All_of_Us_Research_Program_Operational_Protocol_2022.pdf)). Detailed methodologies
533 regarding genotyping, ancestry classification, quality control measures, and the
534 methodology for excluding related participants are thoroughly documented in the
535 AoU Research Program Genomic Research Data Quality Report
536 ([https://support.researchallofus.org/hc/en-us/articles/4617899955092-All-of-Us-
537 Genomic-Quality-Report](https://support.researchallofus.org/hc/en-us/articles/4617899955092-All-of-Us-Genomic-Quality-Report)).

538 We conducted our analysis on short-read whole exome sequencing data (version
539 7.1), focusing on two phenotypes: BMI and T2D. The analysis encompassed
540 219,015 unrelated individuals, including 112,526 of European ancestry, 46,414 of
541 African/African American ancestry, 34,865 of American Admixed/ Latino and 25,210
542 various other ancestries (Supplementary Table 3 for detailed sample size
543 information).

544 BMI data were derived from the “body mass index (BMI) [Ratio]” metric (Concept Id
545 3038553) within the “Labs and Measurements” domain. The “Type 2 diabetes
546 mellitus” identifier (Concept Id 201826) in the “Conditions” domain facilitated the
547 identification of T2D cases. For participants with multiple BMI/T2D records, the initial

548 entry was utilized. The participants' ages were calculated by subtracting the birth
549 year from the timestamp of the earliest record. Among these individuals, 32,462
550 were identified as T2D cases, and 186,553 served as controls. Only subjects aged
551 over 18 were included in the analyses.

552 Gene-based burden tests were applied to variants with MAF less than 0.001. These
553 tests were conducted using STAAR (variant-set test for association using annotation
554 information)⁵⁹ implemented in STAARpipeline⁶⁰ (R package version 0.9.7), with
555 covariates adjustments for age, age², sex, age*sex, and the first 16 PCs. The criteria
556 for gene-burden masks followed the methodology of the main UKB analyses.

557

558 **UK Biobank whole-exome sequencing processing**

559 To quantify the gain from WGS vs WES in UK Biobank, we compared variant counts
560 between our WGS data with those from the 450K OQFE (original quality functional
561 equivalence) release of the UK Biobank WES data (454,756 individuals total). We
562 processed multi-sample pVCFs using Hail⁵³ 0.2, where multi-allelic sites were first
563 split and normalized. Sites were then excluded if they failed the following quality
564 metrics: for SNPs, ABHet < 0.175, QD < 2, QUAL < 30, SOR > 30, FS > 60, MQ <
565 40, MQRankSum < -12.5 and ReadPosRankSum < -8; for indels: ABHet < 0.175, QD
566 < 2, QUAL < 30, FS > 200 and ReadPosRankSum < -20, resulting in 23,273,514
567 variants available for analysis. Individuals with high heterozygosity rates, discordant
568 WES genotypes compared to array and discordant reported versus genetic sex were
569 removed, resulting in 453,931 individuals. Variants were annotated using the
570 identical VEP pipeline, LOFTEE, CADD and REVEL annotations as described for
571 WGS.

572

573 **Phenotypic association scan of identified BMI and T2D associated genes in** 574 **UKBB**

575 We ran association tests between each identified genes carriers and a list of
576 representative phenotypes (full list can be found in Supplementary Table 7 and 8)
577 available in the UK Biobank using R v4.0.2 including the same covariates we used in
578 our genome-wide gene burden tests. We also extracted the phenotypic associations
579 with $P < 0.05$ for all genes we identified in our analysis from AstraZeneca PheWAS
580 Portal⁶¹ (version: UK Biobank 470K WES v5, Supplementary Table 9 and 10).

581

582 **BMI and T2D GWAS lookup**

583 Identified genes were queried for proximal BMI and T2D GWAS signals, using data
584 from the largest published GWAS meta-analyses. For BMI, we used data from the
585 GIANT consortium⁶², which includes data on up to 806,834 individuals. For T2D, we
586 used data from the DIAGRAM consortium⁶³, which included up to 428,452 T2D
587 cases and 2,107,149 controls.

588 For each of these GWAS, we performed signal selection and prioritised causal
589 GWAS genes using the “GWAS to Genes” pipeline as described elsewhere¹⁸. The
590 previously identified genes were annotated if their start or end sites were within
591 500kb up- or downstream of GWAS signals in the two meta-analyses, using the
592 NCBI RefSeq gene map for GRCh37, and overlaid with further supporting
593 functional dataset information. For further details about the specific application of this
594 method, see Kentistou et al.¹⁸

595

596

597 **Competing interests**

598

599 J.L., A.C., Y.L., J.D., C.B-D. and R.S. are employees and stockholders of GSK.

600 J.R.B.P. and E.J.G. are employees and shareholders of Insmmed. J.R.B.P. receives

601 research funding from GSK. Y.Z. is a UK University worker at GSK. S.O.R. has

602 undertaken remunerated consultancy work for Pfizer, Third Rock Ventures,

603 AstraZeneca, NorthSea Therapeutics and Courage Therapeutics. The other authors

604 declare no competing interests.

605

606 **Code availability**

607

608 All analyses were performed used publicly available softwares. No custom code was

609 developed.

610

611 **Data Accessibility**

612

613 The UK Biobank phenotype, whole-genome and whole-exome sequencing data

614 described here are publicly available to registered researchers through the UKB data

615 access protocol. Information about registration for access to the data is available at:

616 <https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access>. Data for this

617 study were obtained under Resource Application Numbers: 20361 and 68574.

618

619 The All of Us phenotype and whole-genome sequencing data described here are

620 available to registered researchers through the All of Us data access protocol.

621 Information about registration for access to the data is available at:

622 <https://www.researchallofus.org/register/> .

623

624

625 References

- 626 1. Backman, J. D. *et al.* Exome sequencing and analysis of 454,787 UK Biobank
627 participants. *Nature* **599**, 628–634 (2021).
- 628 2. Tam, V. *et al.* Benefits and limitations of genome-wide association studies. *Nat*
629 *Rev Genet* **20**, 467–484 (2019).
- 630 3. Loos, R. J. F. & Yeo, G. S. H. The genetics of obesity: from discovery to
631 biology. *Nat Rev Genet* **23**, 120–133 (2022).
- 632 4. Uffelmann, E. *et al.* Genome-wide association studies. *Nature Reviews*
633 *Methods Primers* **2021 1:1 1**, 1–21 (2021).
- 634 5. Lam, B. Y. H. *et al.* MC3R links nutritional state to childhood growth and the
635 timing of puberty. *Nature* **599**, 436–441 (2021).
- 636 6. Halldorsson, B. V. *et al.* The sequences of 150,119 genomes in the UK
637 Biobank. *Nature* **607**, 732–740 (2022).
- 638 7. Li, S., Carss, K. J., Halldorsson, B. V, Cortes, A. & Consortium, U. B. W.-G. S.
639 Whole-genome sequencing of half-a-million UK Biobank participants. *medRxiv*
640 2023.12.06.23299426 (2023) doi:10.1101/2023.12.06.23299426.
- 641 8. Akbari, P. *et al.* Sequencing of 640,000 exomes identifies GPR75 variants
642 associated with protection from obesity. *Science* **373**, (2021).
- 643 9. Zhao, Y. *et al.* Protein-truncating variants in BSN are associated with severe
644 adult-onset obesity, type 2 diabetes and fatty liver disease. *Nat Genet* **56**,
645 579–584 (2024).
- 646 10. Kaisinger, L. R. *et al.* Large-scale exome sequence analysis identifies sex- and
647 age-specific determinants of obesity. *Cell genomics* **3**, (2023).
- 648 11. Gardner, E. J. *et al.* Damaging missense variants in IGF1R implicate a role for
649 IGF-1 resistance in the etiology of type 2 diabetes. *Cell genomics* **2**, (2022).
- 650 12. Nag, A. *et al.* Human genetics uncovers MAP3K15 as an obesity-independent
651 therapeutic target for diabetes. *Sci Adv* **8**, (2022).
- 652 13. Zhao, Y. *et al.* GIGYF1 loss of function is associated with clonal mosaicism
653 and adverse metabolic health. *Nat Commun* **12**, (2021).
- 654 14. Zhu, N. *et al.* Rare predicted loss of function alleles in Bassoon (BSN) are
655 associated with obesity. *NPJ Genom Med* **8**, (2023).
- 656 15. Ioannidis, N. M. *et al.* REVEL: An Ensemble Method for Predicting the
657 Pathogenicity of Rare Missense Variants. *Am J Hum Genet* **99**, 877–885
658 (2016).
- 659 16. Escribano-Díaz, C. *et al.* A cell cycle-dependent regulatory circuit composed of
660 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. *Mol Cell*
661 **49**, 872–883 (2013).

- 662 17. Tasaki, T. *et al.* Biochemical and genetic studies of UBR3, a ubiquitin ligase
663 with a function in olfactory and other sensory systems. *J Biol Chem* **282**,
664 18510–18520 (2007).
- 665 18. Kentistou, K. A. *et al.* Understanding the genetic complexity of puberty timing
666 across the allele frequency spectrum. *medRxiv* (2023)
667 doi:10.1101/2023.06.14.23291322.
- 668 19. Deng, S., McTiernan, N., Wei, X., Arnesen, T. & Marmorstein, R. Molecular
669 basis for N-terminal acetylation by human NatE and its modulation by HYPK.
670 *Nat Commun* **11**, (2020).
- 671 20. Yong, X. *et al.* Cryo-EM structure of the Mon1-Ccz1-RMC1 complex reveals
672 molecular basis of metazoan RAB7A activation. *Proc Natl Acad Sci U S A* **120**,
673 (2023).
- 674 21. van den Boomen, D. J. H. *et al.* A trimeric Rab7 GEF controls NPC1-
675 dependent lysosomal cholesterol export. *Nat Commun* **11**, (2020).
- 676 22. Nag, A. *et al.* Effects of protein-coding variants on blood metabolite
677 measurements and clinical biomarkers in the UK Biobank. *Am J Hum Genet*
678 **110**, 487–498 (2023).
- 679 23. Jänne, M. & Hammond, G. L. Hepatocyte nuclear factor-4 controls
680 transcription from a TATA-less human sex hormone-binding globulin gene
681 promoter. *J Biol Chem* **273**, 34105–34114 (1998).
- 682 24. Araki, E. *et al.* Alternative pathway of insulin signalling in mice with targeted
683 disruption of the IRS-1 gene. *Nature* **372**, 186–190 (1994).
- 684 25. Tamemoto, H. *et al.* Insulin resistance and growth retardation in mice lacking
685 insulin receptor substrate-1. *Nature* **372**, 182–186 (1994).
- 686 26. Withers, D. J. *et al.* Disruption of IRS-2 causes type 2 diabetes in mice. *Nature*
687 **391**, 900–904 (1998).
- 688 27. Tasaki, T. *et al.* A family of mammalian E3 ubiquitin ligases that contain the
689 UBR box motif and recognize N-degrons. *Mol Cell Biol* **25**, 7120–7136 (2005).
- 690 28. Varshavsky, A. N-degron and C-degron pathways of protein degradation. *Proc*
691 *Natl Acad Sci U S A* **116**, 358–366 (2019).
- 692 29. Meisenberg, C. *et al.* Ubiquitin ligase UBR3 regulates cellular levels of the
693 essential DNA repair protein APE1 and is required for genome stability.
694 *Nucleic Acids Res* **40**, 701–711 (2012).
- 695 30. Gao, S. *et al.* UBR2 targets myosin heavy chain IIb and IIx for degradation:
696 Molecular mechanism essential for cancer-induced muscle wasting. *Proc Natl*
697 *Acad Sci U S A* **119**, (2022).
- 698 31. Hockerman, G. H. *et al.* The Ubr2 Gene is Expressed in Skeletal Muscle
699 Atrophying as a Result of Hind Limb Suspension, but not Merg1a Expression
700 Alone. *Eur J Transl Myol* **24**, (2014).

- 701 32. Kwak, K. S. *et al.* Regulation of protein catabolism by muscle-specific and
702 cytokine-inducible ubiquitin ligase E3 α -II during cancer cachexia. *Cancer*
703 *Res* **64**, 8193–8198 (2004).
- 704 33. All of Us Research Program Genomics Investigators. Genomic data in the All
705 of Us Research Program. *Nature* **627**, 340–346 (2024).
- 706 34. Semple, R. K., Savage, D. B., Cochran, E. K., Gorden, P. & O’Rahilly, S.
707 Genetic syndromes of severe insulin resistance. *Endocr Rev* **32**, 498–514
708 (2011).
- 709 35. George, S. *et al.* A family with severe insulin resistance and diabetes due to a
710 mutation in AKT2. *Science* **304**, 1325–1328 (2004).
- 711 36. Chudasama, K. K. *et al.* SHORT syndrome with partial lipodystrophy due to
712 impaired phosphatidylinositol 3 kinase signaling. *Am J Hum Genet* **93**, 150–
713 157 (2013).
- 714 37. Thauvin-Robinet, C. *et al.* PIK3R1 mutations cause syndromic insulin
715 resistance with lipoatrophy. *Am J Hum Genet* **93**, 141–149 (2013).
- 716 38. Dymont, D. A. *et al.* Mutations in PIK3R1 cause SHORT syndrome. *Am J Hum*
717 *Genet* **93**, 158–166 (2013).
- 718 39. Kahn, C. R. *et al.* The syndromes of insulin resistance and acanthosis
719 nigricans. Insulin-receptor disorders in man. *N Engl J Med* **294**, 739–745
720 (1976).
- 721 40. Lin, X. *et al.* Dysregulation of insulin receptor substrate 2 in beta cells and
722 brain causes obesity and diabetes. *J Clin Invest* **114**, 908–916 (2004).
- 723 41. Lay, A. C. & Coward, R. J. M. The Evolving Importance of Insulin Signaling in
724 Podocyte Health and Disease. *Front Endocrinol (Lausanne)* **9**, (2018).
- 725 42. Santamaria, B. *et al.* IRS2 and PTEN are key molecules in controlling insulin
726 sensitivity in podocytes. *Biochim Biophys Acta* **1853**, 3224–3234 (2015).
- 727 43. Welsh, G. I. *et al.* Insulin signaling to the glomerular podocyte is critical for
728 normal kidney function. *Cell Metab* **12**, 329–340 (2010).
- 729 44. Carew, R. M. *et al.* Deletion of *Irs2* causes reduced kidney size in mice: role
730 for inhibition of GSK3 β ? *BMC Dev Biol* **10**, (2010).
- 731 45. Luyckx, V. A. *et al.* Nephron overload as a therapeutic target to maximize
732 kidney lifespan. *Nat Rev Nephrol* **18**, 171–183 (2022).
- 733 46. Gnudi, L., Coward, R. J. M. & Long, D. A. Diabetic Nephropathy: Perspective
734 on Novel Molecular Mechanisms. *Trends Endocrinol Metab* **27**, 820–830
735 (2016).
- 736 47. White, M. F. IRS proteins and the common path to diabetes. *Am J Physiol*
737 *Endocrinol Metab* **283**, (2002).

- 738 48. Brady, M. J. IRS2 takes center stage in the development of type 2 diabetes. *J*
739 *Clin Invest* **114**, 886–888 (2004).
- 740 49. Ahlqvist, E., Prasad, R. B. & Groop, L. Subtypes of Type 2 Diabetes
741 Determined From Clinical Parameters. *Diabetes* **69**, 2086–2093 (2020).
- 742 50. Winters, S. J., Scoggins, C. R., Appiah, D. & Ghooray, D. T. The hepatic
743 lipidome and HNF4 α and SHBG expression in human liver. *Endocr Connect* **9**,
744 1009–1018 (2020).
- 745 51. Parker, V. E. R. & Semple, R. K. Genetics in endocrinology: genetic forms of
746 severe insulin resistance: what endocrinologists should know. *Eur J Endocrinol*
747 **169**, (2013).
- 748 52. Eggertsson, H. P. *et al.* GraphTyper enables population-scale genotyping using
749 pangenome graphs. *Nat Genet* **49**, 1654–1660 (2017).
- 750 53. GitHub - hail-is/hail: Cloud-native genomic dataframes and batch computing.
751 <https://github.com/hail-is/hail>.
- 752 54. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**,
753 (2016).
- 754 55. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from
755 variation in 141,456 humans. *Nature* **581**, 434–443 (2020).
- 756 56. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD:
757 predicting the deleteriousness of variants throughout the human genome.
758 *Nucleic Acids Res* **47**, D886–D894 (2019).
- 759 57. Loh, P. R., Kichaev, G., Gazal, S., Schoech, A. P. & Price, A. L. Mixed-model
760 association for biobank-scale datasets. *Nat Genet* **50**, 906–908 (2018).
- 761 58. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger
762 and richer datasets. *Gigascience* **4**, (2015).
- 763 59. Li, X. *et al.* Dynamic incorporation of multiple in silico functional annotations
764 empowers rare variant association analysis of large whole-genome
765 sequencing studies at scale. *Nat Genet* **52**, 969–983 (2020).
- 766 60. Li, Z. *et al.* A framework for detecting noncoding rare-variant associations of
767 large-scale whole-genome sequencing studies. *Nat Methods* **19**, (2022).
- 768 61. Wang, Q. *et al.* Rare variant contribution to human disease in 281,104 UK
769 Biobank exomes. *Nature* **597**, 527–532 (2021).
- 770 62. Yengo, L. *et al.* Meta-analysis of genome-wide association studies for height
771 and body mass index in ~700000 individuals of European ancestry. *Hum Mol*
772 *Genet* **27**, 3641–3649 (2018).
- 773 63. Suzuki, K. *et al.* Genetic drivers of heterogeneity in type 2 diabetes
774 pathophysiology. *Nature* **627**, 347–357 (2024).

775